Article Details
Retrieved on: 2025-01-08 15:40:08
Tags for this article:
Click the tags to see associated articles and topics
Summary
UBS's analysis on Pfizer highlights challenges in the biopharma sector, particularly against a backdrop of financial market uncertainties and potential legislative changes under Trump. The firm lowers Pfizer's price target, signaling concerns for short-term performance.
Article found on: markets.businessinsider.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here